Intensive Studies for Recertification: Pharmacotherapy (Cert # L219018)

ACPE Numbers: 
0204-0000-20-322-H01-P
0204-0000-20-294-H04-P
0204-0000-20-248-H01-P
0204-0000-20-293-H01-P

Content Release Date: 02/03/2021
Expiration Date: 02/01/2022
Activity Type: Application-based
CE Credits: 6.0 hours
Activity Fee: $100 (ASHP member); $150 (non-member)

Accreditation for Pharmacists

 The American Society of Health-System Pharmacists and the American Pharmacists Association (APhA) are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

These activities were presented as part of the 2020 Virtual Midyear Clinical Meeting. Learners who claimed ACPE credit for these activities as part of that meeting, should not claim ACPE credit again.

Target Audience

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

  • Cardiovascular Disease
  • P Values in Statistical Reporting
  • Factor Xa inhibitors
  • Drug Monitoring

Activity Overview

The Intensive Study Package is intended for board-certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues in pharmacotherapy.

The Pharmacotherapy Intensive Study Recertification Package consists of 4 activities (see table below) and provides up to 6.0 hours of continuing pharmacy education and/or recertification credit.  

These activities are part of the ASHP professional development program for BCPS recertification approved by the BPS.  For pharmacists who maintain more than one certification, three of the activities are approved for multiple specialties (see table below).

Recertification Credit*

Board-certified pharmacists are eligible to receive up to 6.0 hours of recertification credit for completing this package. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Module

ACPE Number

Credit Hours

Specialty

*Assessment Pass Point

Beyond the Standard: Maximizing Treatment to Reduce Residual Cardiovascular Disease Risk

0204-0000-20-322-H01-P

1.5

BCPS

70%

P  VALUEable? Purpose, Use, and the Evolution of P Values in Statistical Reporting

0204-0000-20-294-H04-P

1.5

BCPS, BCCCP, BCPPS

64%

Anti(X)dotes for All? The Role of Replacement and Reversal Strategies in Managing Life-Threatening Bleeding and Emergent Procedures for Patients on Factor Xa inhibitors

0204-0000-20-248-H01-P

1.5

BCPS, BCCCP

71%

Vancomycin Therapeutic Drug Monitoring – The Times They Are a Changin’

0204-0000-20-293-H01-P

1.5

BCPS, BCCCP

71%

 

Learning Objectives

0204-0000-20-322-H01-P

Learning Objectives

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Discuss current guideline recommendations for reducing cardiovascular disease risk.
  • Develop a combination antiplatelet and anticoagulant treatment regimen for a patient with underlying cardiovascular disease.
  • Apply the results of lipid lowering trials to reduce the risk of cardiovascular for a patient with underlying cardiovascular disease.
  • Design a treatment regimen for a patient that both improves glycemic control and lowers cardiovascular risk.
  • Design a medication regimen to reduce the risk of cardiovascular disease in a patient with underlying cardiovascular disease.

This activity is approved for Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.

0204-0000-20-294-H04-P

Learning Objectives

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Summarize recent trends in medical literature related to significance testing.
  • Compare your current practice when discussing statistical significance to recent recommendations.
  • Interpret p values, meanings, limitations, and appropriate use.
  • Select alternative methodologies for interpretation of significance testing.

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP), Board Certified Pediatric Pharmacy Specialist (BCPPS), and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.

0204-0000-20-248-H01-P

Learning Objectives

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Select appropriate hemostatic therapy for patients presenting with acute, life-threatening hemorrhage due to factor Xa inhibitors.
  • Recommend appropriate hemostatic therapy for patients requiring emergent surgery while on factor Xa inhibitors.
  • Recommend initial anticoagulant therapy following coagulation factor Xa (recombinant), inactivated-zhzo administration.
  • Develop clinical pathways for efficient use of hemostatic agents in the setting of factor Xa inhibitor use.
  • Design evidence-based strategies for monitoring coagulation status following coagulation factor Xa (recombinant), inactivated-zhzo administration.

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP) and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.

0204-0000-20-293-H01-P

Learning Objectives

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Design optimized vancomycin dosing schemes using vancomycin pharmacodynamic and toxicodynamic principles and current evidence.
  • Compute vancomycin area under the concentration-time curve using 2 sample pharmacokinetics and modified trapezoidal rule.
  • Describe how to use Bayesian Software to generate vancomycin area under the concentration-time curve.
  • Design a program for vancomycin therapeutic drug monitoring by area under the concentration-time curve.

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP) and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.

Planners, Presenters, and Reviewers 

Full Faculty Bios

Associate Professor
University of Colorado
Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado

Professor
Department of Clinical and Administrative Sciences & Cardiology Clinical Pharmacy Special
Sullivan University
College of Pharmacy & Health Sciences
Louisville, Kentucky

Professor of Pharmacy Practice
MCPHS University
Framingham, Massachusetts

Assistant Professor of Clinical Pharmacy
Philadelphia College of Pharmacy at University of the Sciences
Philadelphia, Pennsylvania
Clinical Pharmacy Specialist
Cooper University Hospital
Camden, New Jersey

Associate Professor
Sullivan University
College of Pharmacy and Health Sciences
Louisville, Kentucky

Associate Dea
Jefferson College of Pharmacy
Philadelphia, Pennsylvania

Professor of Pharmacy Practice
University of Oklahoma College of Pharmacy

Clinical Specialist – Medicine Critical Care
Barnes Jewish Hospital
Saint Louis, Missouri

Pharmacy Manager
Investigational Drug Service
University of Utah Health
Salt Lake City, Utah

ASP/Infectious Diseases Clinical Pharmacist
Stanford Health Care
Stanford, California

Associate Professor
University of Oklahoma College of Pharmacy

Clinical Specialist
Infectious Diseases
Houston Methodist Health System
Houston, Texas

Professor and Infectious Diseases Clinical Specialist
West Virginia University (WVU) and WVU Hospitals and Clinics
Canonsburg, Pennsylvania

Pharmacy Manager
Brigham and Women’s Hospital
Boston, Massachusetts

Clinical Pharmacy Practice Manager
Brigham and Women's Hospital
Foxboro, Massachusetts

Pediatric Oncology Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center

Assistant Professor
Touro University California
College of Pharmacy
Vallejo, California

*Content Matter Experts

Holly L. Byrnes, Pharm D., BCPS
Susan R. Dombrowski, M.S., R.Ph.
Kristi Hofer, Pharm.D.
Robert Tremmel, Pharm.D.

Hakeem Abayomi, Pharm.D, BCPS, BCPPs
Shannon Allcron, Pharm.D., BCCCP, BCPS
Hadriana Angerbauer, Pharm.D., BCPS
Craig Aumack, Pharm.D., BCPS
Kelly Bach, Pharm.D., BCPS, BCCCP, BCGP
Daniel Baker, Pharm.D., BCPS, BCCCP, BCIDP
Brian Baum, Pharm.D., M.B.A., M.S., BCPS, BCCCP
Angel Becker, Pharm.D., BCPS
Andrew Bohrer, Pharm.D., BCPS
Jeffrey Bruno, Pharm.D., BCPS, BCNSP, BCCCP
Chad Cannon, Pharm.D., BCCCP, BCIDP
Laura Celmins, Pharm.D., BCPS, BCCCP
Rou-Yee Chenhsu, Pharm.D., BCPS, BCPPS
Jennifer Cole, Pharm.D., BCPS, BCCCP
Kelli Crowley, Pharm.D., BCPS, BCPPS
Robert Dannemiller, Pharm.D., BCPS, BCCCP, R.Ph.
Tuong Diep, Pharm. D., BCPS, BCCCP, BCIDP
Roxana Dumitru, Pharm.D., BCPS, BCCCP
Gina Gries, Pharm.D., BCPS, BCPPS
Kevin Guffey, B.S.Pharm., Pharm.D., M.B.A., BCPS, BCCCP, BCNSP, CNSC
Brianne Hansen, Pharm.D., BCPS, BCCCP
Coleen Hart, Pharm.D., BCPS, BCCCP
Margaret Heger, Pharm.D., BCPS, BCPPS
Janelle Hickey, Pharm.D., BCPS, BCCCP
Mylinh Ho, Pharm.D., BCPS, BCCCP
Alyssa Hobby, Pharm.D., BCPPS
Kelly Hummel, Pharm.D., BCPS, BCPPS
Ramzan Judge, Pharm.D., BCCCP
Emily Kurzen, Pharm.D., BCPPS
Noelle Kwan, Pharm.D., BCPS
Daisy Leong, Pharm.D., BCPS
Thien Lutts , B.S.Pharm., CPS, BCCCP
Michael McQuade, Pharm.D., BCCCP, BCPS
Brian Murray, Pharm.D., BCCCP
Paige Newman, Pharm.D., BCPS, BCCCP
Chris Oswald, Pharm.D., BCPS, BCCCP
Cara Phillips, Pharm.D., BCPS, BCCCP
Hal Piwonka, Pharm.D., BCCCP
Jennifer Polyniak, Pharm.D., BCPS, BCCCP
Kaitlin Pruskowski, Pharm.D., BCPS, BCCCP
David Reynolds, Pharm.D., BCPS, BCCCP
Emily Rowe, Pharm.D., M.S., BCPPS, BCPS
Julie Safirstein, Pharm.D., BCPS
Michael Semanco, Pharm.D., BCPS, BCCCP
Stephanie Sexton, Pharm.D., BCCCP
Anna Simmont, Pharm.D., BCPS, BCPPS
Priyanka Singh, Pharm.D., BCPS, BCCCP
Melanie Sisco, Pharm.D., BCPS, CSNC
Beata Slomiany Mears, Pharm.D., BCCCP
Zachary Smith, Pharm.D., BCPS, BCCCP
Ashley Stajkowski, Pharm.D., BCPS
Terri Tieman, Pharm.D., BCPS, BCCCP
Barbara Wiggins, Pharm.D., M.B.A., BCPS, BCCP, BCCCP

 

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Snehal Bhatt: Speakers Bureau and Advisory Board, Portola Pharmaceuticals
  • All other staff, program chairs, presenters, and reviewers report no financial relationships relevant to this activity.

Methods and CE Requirements

Activities consist of audio/ video/PDF files, an attestation statement, and activity evaluation. Learners must review all content and complete the attestation statement and course evaluation to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 

Development

These activities were developed by ASHP.